Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Sirolimus (Primary) ; Mesenchymal stem cell therapy; Mycophenolate mofetil; Mycophenolate sodium; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TEACH
- 23 Apr 2019 Planned End Date changed from 1 Aug 2025 to 1 Oct 2025.
- 23 Apr 2019 Planned primary completion date changed from 1 Aug 2025 to 1 Oct 2023.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.